Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
356.22122616
InChI
InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)
InChI Key
InChIKey=PJBFVWGQFLYWCB-UHFFFAOYSA-N
IUPAC Name
1,3-dipropyl-8-{tricyclo[3.3.1.0^{3,7}]nonan-3-yl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione
Traditional IUPAC Name
rolofylline
SMILES
CCCN1C2=C(NC(=N2)C23CC4CC2CC(C3)C4)C(=O)N(CCC)C1=O
pKa (strongest acidic)
7.83
pKa (Strongest Basic)
-0.72
Refractivity
99.06 m3·mol-1
Cơ Chế Tác Dụng :
KW-3902 is a compounds that is under clinical development by pharmaceutical company, NovaCardia. It is used for the treatment of congestive heart failure.
KW-3902 (rolofylline),is an adenosine A1-receptor antagonist, on diuresis and renal function compared with placebo in patients with acute decompensated heart failure (ADHF). Plasma adenosine levels are elevated in patients with heart failure and adenosine A1 receptors in the kidney mediate vasoconstriction of afferent arterioles, reabsorption of sodium and water in proximal tubules, and tubuloglomerular feedback in the juxtaglomerular apparatus. Accordingly, inhibition of these receptors would be expected to increase renal blood flow and enhance diuresis. The effects of KW-3902 on renal function are consistent with those obtained with another adenosine A1-receptor antagonist in both experimental and human heart failure.
Chỉ Định :
Investigated for use/treatment in congestive heart failure and kidney disease.